Chang-Ki Lim

Title: Chang-Ki Lim: Innovator in Polypeptide Drug Development

Introduction

Chang-Ki Lim is a notable inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of polypeptide drugs. His innovative work focuses on enhancing the stability and efficacy of therapeutic proteins.

Latest Patents

Chang-Ki Lim holds a patent for a "Physiologically active polypeptide conjugate having prolonged in vivo half-life." This invention involves a protein conjugate that includes a physiologically active polypeptide, a non-peptidic polymer, and an immunoglobulin. The conjugate is designed to improve the in vivo stability and prolong the half-life of the polypeptide in blood, while minimizing the risk of inducing an immune response. He has 1 patent to his name.

Career Highlights

Chang-Ki Lim is currently associated with Hanmi Holdings Co., Ltd., a prominent company in the pharmaceutical industry. His work at Hanmi has been pivotal in advancing drug development processes and enhancing therapeutic options for patients.

Collaborations

Chang-Ki Lim has collaborated with notable colleagues, including Young-Min Kim and Dae-Jin Kim. These partnerships have fostered innovation and contributed to the successful development of new therapeutic solutions.

Conclusion

Chang-Ki Lim's contributions to the field of polypeptide drug development highlight his role as an influential inventor. His innovative approaches continue to shape the future of biopharmaceuticals, making significant strides in patient care.